Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis

dc.authorscopusid6507324756
dc.authorscopusid6505767681
dc.authorscopusid6506874350
dc.authorscopusid18433670800
dc.authorscopusid22333972200
dc.authorscopusid56665283100
dc.authorscopusid6701334317
dc.contributor.authorAkarirmak Ü.
dc.contributor.authorKoçyiğit H.
dc.contributor.authorEskiyurt N.
dc.contributor.authorEsmaeilzadeh S.
dc.contributor.authorKuru O.
dc.contributor.authorYalçinkaya E.Y.
dc.contributor.authorPeker O.
dc.date.accessioned2024-06-12T10:25:39Z
dc.date.available2024-06-12T10:25:39Z
dc.date.issued2016
dc.description.abstractObjective: In our study, we aimed to evaluate the influence of training on compliance and persistence with bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosis patients. Methods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2 ± 7.2 years) were included in this national, multicenter, prospective non-interventional observational cohort registry study. Patients were randomized into training (n = 492, 50.3%, mean age: 63.4 ± 7.2 years) and control (n = 487, 49.7%, mean age: 63.0 ± 7.1 years) groups. Patients in each intervention group were given weekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%, respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-month intervals throughout 12 months of treatment for evaluation of persistence, compliance and adverse events. Results: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 days of duration during the 12-month follow-up period. The mean compliance in the compliant and fully compliant group remained at an average of 86.6%. No significant difference was detected between the training and control groups in terms of compliance and persistence. Significantly longer persistence (360.0 ± 89.0 vs. 345.0 ± 108.0 days; p = 0.035), higher percentage of persistent patients (83.4% vs. 74.2%; p = 0.012) and higher compliance rates (88.8% vs. 83.3%; p = 0.002) were noted in monthly regimen patients in comparison to those given weekly regimen. © 2016 Turkish Association of Orthopaedics and Traumatology.en_US
dc.identifier.doi10.1590/S0080-623420160000500008
dc.identifier.endpage599en_US
dc.identifier.issn1017-995X
dc.identifier.issue4en_US
dc.identifier.pmid27524671en_US
dc.identifier.scopus2-s2.0-84994106436en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage592en_US
dc.identifier.urihttps://doi.org/10.1590/S0080-623420160000500008
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16458
dc.identifier.volume50en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Association of Orthopaedics and Traumatologyen_US
dc.relation.ispartofActa Orthopaedica et Traumatologica Turcicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBisphosphonate; Compliance; Dosing Regimen; Osteoporosis; Persistence; Trainingen_US
dc.subjectBisphosphonic Acid Derivative; Bone Density Conservation Agent; Aged; Clinical Trial; Controlled Study; Drug Administration; Female; Human; Medication Compliance; Middle Aged; Multicenter Study; Osteoporosis, Postmenopausal; Patient Education; Procedures; Prospective Study; Randomized Controlled Trial; Statistics And Numerical Data; Turkey; Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Education As Topic; Prospective Studies; Turkeyen_US
dc.titleInfluence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosisen_US
dc.typeArticleen_US

Dosyalar